Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: Report from the SENTRY Antimicrobial Surveillance Program (2001-2004)

Diagnostic Microbiology and Infectious Disease

Volumn 54, Issue 3, 2006, Pages 157-164

  Deshpande, Lalitagauri M ^a   Sader, Helio S ^a   Debbia, Eugenio ^b   Nicoletti, Giuseppe ^c   Fadda, Giovanni ^d   Jones, Ronald N ^a,e  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clonal dissemination; Fluoroquinolones; Italy; Resistance; Streptococcus pneumoniae

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PHENETICILLIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHICAL VARIATION (SPECIES); ITALY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RIBOTYPING; SEROTYPING; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA;

ANTI-BACTERIAL AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; EPIDEMIOLOGY, MOLECULAR; FLUOROQUINOLONES; HUMANS; ITALY; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; POLYMERASE CHAIN REACTION; RIBOTYPING; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 33644624088     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.08.012     Document Type: Article

References (33)

1. S.M. Bhavnani, J.P. Hammel, R.N. Jones, and P.G. Ambrose Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States Diagn. Microbiol. Infect. Dis. 51 2005 31 37
2. D. Bogaert, R.H. Veenhoven, M. Sluijter, W.J. Wannet, G.T. Rijkers, T.J. Mitchell, S.C. Clarke, W.H. Goessens, A.G. Schilder, E.A. Sanders, R. de Groot, and P.W. Hermans Molecular epidemiology of pneumococcal colonization in response to pneumococcal conjugate vaccination in children with recurrent acute otitis media J. Clin. Microbiol. 43 2005 74 83
3. D.K. Chen, A. McGeer, J.C. de Azavedo, and D.E. Low Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network N. Engl. J. Med. 341 1999 233 239
4. Clinical and Laboratory Standards Institute Performance standard for antimicrobial susceptibility testing Document M100-S15 2005 CLSI Wayne, PA
5. M.A. de Sousa, I.S. Sanches, M.L. Ferro, M.J. Vaz, Z. Saraiva, T. Tendeiro, J. Serra, and H. de Lencastre Intercontinental spread of a multidrug-resistant methicillin-resistant Staphylococcus aureus clone J. Clin. Microbiol. 36 1998 2590 2596
6. M.J. Ferrandiz, A. Fenoll, J. Linares, and A.G. De La Campa Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae Antimicrob. Agents Chemother. 44 2000 840 847
7. G.Y. Guirao, M.C. Martinez Toldos, B. Mora Peris, M.A. Alonso Manzanares, M.N. Gutierrez Zufiaurre, J.A. Martinez Andres, J.L. Munoz Bellido, J.A. Garcia-Rodriguez, and M. Segovia Hernandez Molecular diversity of quinolone resistance in genetically related clinical isolates of Staphylococcus aureus and susceptibility to newer quinolones J. Antimicrob. Chemother. 47 2001 157 161
8. D.C. Hooper Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance Clin. Infect. Dis. 27 Suppl 1 1998 S54 S63
9. C. Janoir, V. Zeller, M.-D. Kitzis, N.J. Moreau, and L. Gutmann High-level fluoroquinolones resistance in Streptococcus pneumoniae requires mutations in parC and gyrA Antimicrob. Agents Chemother. 40 1996 2760 2764
10. D.B. Jernigan, M.S. Cetron, and R.F. Breiman Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group JAMA 275 1996 206 209
11. R.N. Jones, T.R. Fritsche, and H.S. Sader Therapeutic options among broad-spectrum β-lactams for infections caused by levofloxacin- nonsusceptible Streptococcus pneumoniae Diagn. Microbiol. Infect. Dis. 52 2005 129 133
12. J.H. Jorgensen, L.M. Weigel, B.J. Ferraro, J.M. Swenson, and F.C. Tenover Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gryA, parC and parE loci Antimicrob. Agents Chemother. 43 1999 329 334
13. J.A. Karlowsky, M.E. Jones, D.C. Draghi, and D.F. Sahm Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime Antimicrob. Agents Chemother. 47 2003 3155 3160
14. K. Kawamura-Sato, T. Hasegawa, K. Torii, H. Ito, and M. Ohta Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones Curr. Microbiol. 2005 (in press)
15. K.P. Klugman The role of clonality in the global spread of fluoroquinolone-resistant bacteria Clin. Infect. Dis. 36 2003 783 785
16. N. Korzheva, T.A. Davies, and R. Goldschmidt Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of parC topoisomerase IV and gyrA DNA gyrase subunits from recent fluoroquinolone- resistant Streptococcus pneumoniae clinical isolates Antimicrob. Agents Chemother. 49 2005 2479 2486
17. A. Marchese, M. Ramirez, G.C. Schito, and A. Tomasz Molecular epidemiology of penicillin-resistant Streptococcus pneumoniae isolates recovered in Italy from 1993 to 1996 J. Clin. Microbiol. 36 1998 2944 2949
18. S.M. McChlery, K.J. Scott, and S.C. Clarke Clonal analysis of invasive pneumococcal isolates in Scotland and coverage of serotypes by the licensed conjugate polysaccharide pneumococcal vaccine: possible implications for UK vaccine policy Eur. J. Clin. Microbiol. Infect. Dis. 8 2005 (in press)
19. L. McGee, L. McDougal, J. Zhou, B.G. Spratt, F.C. Tenover, R. George, R. Hakenbeck, W. Hryniewicz, J.C. Lefevre, A. Tomasz, and K.P. Klugman Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network J. Clin. Microbiol. 39 2001 2565 2571
20. M.P. Montanari, E. Tili, I. Cochetti, M. Mingoia, A. Manzin, and P.E. Varaldo Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy Microb. Drug Resist. 10 2004 209 217
21. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically Document M7-A6 2003 NCCLS Wayne, PA
22. E. Pestova, R. Beyer, N.P. Cianciotto, G.A. Noskin, and L.R. Peterson Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones J. Antimicrob. Agents Chemother. 43 1999 2000 2004
23. M.A. Pfaller, R.J. Hollis, and H.S. Sader PFGE analysis of chromosomal restriction fragments H.D. Isenberg Clinical microbiology procedures handbook (Supplement 1) 1992 ASM Press Washington, DC 10.5.c.1 10.5.c.11
24. M.W. Pletz, L. McGee, O. Burkhardt, H. Lode, and K.P. Klugman Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infections following prior ciprofloxacin therapy Eur. J. Clin. Microbiol. Infect. Dis. 24 2005 58 60
25. R.R. Razonable, M.R. Litzow, Y. Khaliq, K.E. Piper, M.S. Rouse, and R. Patel Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis Clin. Infect. Dis. 34 2002 1469 1474
26. R.R. Reinert, S. Reinert, M. van der Linden, M.Y. Cil, A. Al-lahham, and P. Appelbaum Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003 Antimicrob. Agents Chemother. 49 2005 2903 2913
27. S.S. Richter, K.P. Heilmann, S.E. Beekmann, N.J. Miller, C.L. Rice, and G.V. Doern The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations Clin. Infect. Dis. 50 2005 225 235
28. H.S. Sader, T.R. Fritsche, A.H. Mutnick, and R.N. Jones Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002) Diagn. Microbiol. Infect. Dis. 47 2003 515 525
29. T.Y. Sherpa, and H.L. Leaf Pneumococcal vaccination in adults Curr. Infect. Dis. Rep. 7 2005 211 217
30. H.J. Smith, K.A. Nichol, D.J. Hoban, and G.G. Zhanel Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims J. Antmicrob. Chemother. 49 2002 893 895
31. F. Vogel, and H. Scholz PEF-Empfehlungen: Rationaler Einsatz oraler Antibiotika bei Erwachsenen J. Chemother. 2 2002 47 58
32. C. Whitney, M. Farley, J. Hadler, L. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P. Cieslak, M. Cetron, E. Zell, J. Jorgensen, and A. Schuchat Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States N. Engl. J. Med. 343 2000 1917 1924
33. S.-I. Yokota, K. Sato, O. Kuwahara, S. Habadera, N. Tsukamoto, H. Ohuchi, H. Akizawa, T. Himi, and N. Fujii Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan Antimicrob. Agents Chemother. 46 2002 3311 3315